Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7% – Still a Buy?

Shares of Rapport Therapeutics (NASDAQ:RAPP) shot up 5.7% on Wednesday . The stock traded as high as $20.16 and last traded at $20.16. 7,396 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 152,312 shares. The stock had previously closed at $19.07.

Rapport Therapeutics Stock Up 3.6 %

The stock has a fifty day simple moving average of $23.12.

Hedge Funds Weigh In On Rapport Therapeutics

Several large investors have recently made changes to their positions in the company. Values First Advisors Inc. bought a new stake in Rapport Therapeutics during the 3rd quarter worth about $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth approximately $34,000. SG Americas Securities LLC acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth approximately $101,000. Sandia Investment Management LP bought a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $116,000. Finally, MetLife Investment Management LLC acquired a new position in Rapport Therapeutics in the third quarter valued at approximately $117,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.